Management of Antiplatelet Therapy in Patients at Risk for Coronary Stent Thrombosis Undergoing Non-Cardiac Surgery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00003183" target="_blank" >RIV/00216208:11120/11:00003183 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/11:#0000114

Výsledek na webu

<a href="http://dx.doi.org/10.2165/11594260-000000000-00000" target="_blank" >http://dx.doi.org/10.2165/11594260-000000000-00000</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2165/11594260-000000000-00000" target="_blank" >10.2165/11594260-000000000-00000</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Management of Antiplatelet Therapy in Patients at Risk for Coronary Stent Thrombosis Undergoing Non-Cardiac Surgery

Popis výsledku v původním jazyce

Percutaneous coronary interventions (PCIs) have become the most commonly performed coronary revascularization procedures. At the same time, there is an increased likelihood that patients with intracoronary stents will need to undergo surgery. Two seriousconsequences emerge from this situation: (i) stent thrombosis in relation to discontinuation of antiplatelet therapy, and (ii) major bleeding in relation to continuation of antiplatelet therapy. The best solution to overcome the risks resulting from surgery performed in patients after stent implantation is to postpone the operation until after re-endothelialization of the vessel surface is completed. Expert recommendations advise that patients can be sent for non-cardiac surgery 3 months after bare-metal stent PCI and 12 months after drug-eluting stent PCI, with continuation of aspirin therapy. Difficult decisions regarding antiplatelet management arise when a patient that is still receiving dual antiplatelet therapy with aspirin and a

Název v anglickém jazyce

Management of Antiplatelet Therapy in Patients at Risk for Coronary Stent Thrombosis Undergoing Non-Cardiac Surgery

Popis výsledku anglicky

Percutaneous coronary interventions (PCIs) have become the most commonly performed coronary revascularization procedures. At the same time, there is an increased likelihood that patients with intracoronary stents will need to undergo surgery. Two seriousconsequences emerge from this situation: (i) stent thrombosis in relation to discontinuation of antiplatelet therapy, and (ii) major bleeding in relation to continuation of antiplatelet therapy. The best solution to overcome the risks resulting from surgery performed in patients after stent implantation is to postpone the operation until after re-endothelialization of the vessel surface is completed. Expert recommendations advise that patients can be sent for non-cardiac surgery 3 months after bare-metal stent PCI and 12 months after drug-eluting stent PCI, with continuation of aspirin therapy. Difficult decisions regarding antiplatelet management arise when a patient that is still receiving dual antiplatelet therapy with aspirin and a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11506" target="_blank" >NT11506: Perioperační ischemie versus perioperační krvácení při nekardiálních operacích u kardiaků: Studie PRAGUE 14</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Drugs

ISSN

0012-6667

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

14

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

10

Strana od-do

1797-1806

Kód UT WoS článku

000296069300001

EID výsledku v databázi Scopus

—